Related Experiment Video
Updated: Jan 1, 2026
05:50
Subcutaneous Neurotrophin 4 Infusion Using Osmotic Pumps or Direct Muscular Injection Enhances Aging Rat Laryngeal Muscles
Published on: June 13, 2017
8.8K
Pharyngeal Motility Before and After Thyroarytenoid Muscle Botulinum Toxin Injection
Welber Chaves Mororó1, Fernando Augusto Herbella2, Karine Valéria Gonçalves de Oliveira3
1Department of Ear, Nose and Throat, Escola Paulista de Medicina, Federal University of Sao Paulo, Rua Pedro de Toledo 947, Sao Paulo, SP, 04038-002, Brazil. wmororo@unifesp.br.
Dysphagia
|December 22, 2019
Summary
Botulinum toxin type A (BTA) injections can cause dysphagia. This study found that while pharyngeal motility changes after BTA, it does not predict or strongly contribute to post-injection swallowing difficulties.
Area of Science:
- Otolaryngology
- Gastroenterology
- Neurology
Background:
- Botulinum toxin type A (BTA) injections into laryngeal muscles can lead to dysphagia and reduced quality of life (QOL).
- Pharyngeal motility is a potential factor influencing swallowing function after BTA treatment.
Purpose of the Study:
- To evaluate pharyngeal motility using high-resolution manometry (HRM) as a cause for dysphagia after BTA injection.
- To correlate changes in pharyngeal motility with QOL outcomes in patients receiving BTA.
Main Methods:
- Twenty patients underwent HRM before and after BTA injection.
- Dysphagia was assessed using the SWAL-QOL questionnaire.
- Pharyngeal motility parameters including upper esophageal sphincter (UES) function and velopharynx contraction were analyzed.
Main Results:
- 55% of patients reported worsened QOL post-BTA injection.
- Patients with worsened QOL showed decreased UES extension and velopharynx contraction duration.
- However, HRM findings did not predict post-procedure dysphagia, suggesting motility changes are not the primary cause.
Conclusions:
- While BTA injection alters pharyngeal motility, these changes do not appear to be a strong predictor or contributor to post-procedure dysphagia.
- Further research may be needed to identify other factors affecting QOL after laryngeal BTA treatment.
More Related Videos
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
2.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.6K
01:15Myasthenia Gravis: Diagnostic Tests
1.8K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.8K
01:31Skeletal Muscle Relaxants: Therapeutic Uses
826
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
826
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.0K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.0K
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
825
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
825
01:26Muscles of the Anterior Neck
4.4K
The anterior neck muscles are the group of muscles covering the front part of the neck. These muscles are classified into three subgroups. The first one is the superficial muscles, the most visible muscles in the front of the neck. It includes the platysma and sternocleidomastoid. The second group is the suprahyoid muscles, located above the hyoid bone. This group comprises the digastric, mylohyoid, geniohyoid, and stylohyoid. Lastly, the infrahyoid muscles are found below the hyoid bone and...
4.4K